TIMP1 and neoplasm: To overcome these challenges, current strategies emphasize precision inhibition through isoform-specific small molecules [116], TIMP mimetics [26,129], antibodies [130,131], and targeted delivery platforms such as nanoparticles [132,133] and antibody conjugates [134], which aim to restrict the MMP blockade to the tumor microenvironment and reduce systemic side effects.